DOPA-decarboxylase is elevated in CSF, but not plasma, in prodromal and de novo Parkinson’s disease
Ellen Appleton,
Shervin Khosousi,
Michael Ta,
Michael Nalls,
Andrew B. Singleton,
Andrea Sturchio,
Ioanna Markaki,
Wojciech Paslawski,
Hirotaka Iwaki,
Per Svenningsson
Affiliations
Ellen Appleton
Laboratory of Translational Neuropharmacology, Department of Clinical Neuroscience, Karolinska Institutet
Shervin Khosousi
Laboratory of Translational Neuropharmacology, Department of Clinical Neuroscience, Karolinska Institutet
Michael Ta
Center for Alzheimer’s and Related Dementias, National Institute On Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health
Michael Nalls
Center for Alzheimer’s and Related Dementias, National Institute On Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health
Andrew B. Singleton
Center for Alzheimer’s and Related Dementias, National Institute On Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health
Andrea Sturchio
Laboratory of Translational Neuropharmacology, Department of Clinical Neuroscience, Karolinska Institutet
Ioanna Markaki
Laboratory of Translational Neuropharmacology, Department of Clinical Neuroscience, Karolinska Institutet
Wojciech Paslawski
Laboratory of Translational Neuropharmacology, Department of Clinical Neuroscience, Karolinska Institutet
Hirotaka Iwaki
Center for Alzheimer’s and Related Dementias, National Institute On Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health
Per Svenningsson
Laboratory of Translational Neuropharmacology, Department of Clinical Neuroscience, Karolinska Institutet
